BioSpace News Archive

USAntibiotics, the only U.S. manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Patrick Cashman as company president.

Statera BioPharma, a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, provided an update on the integration of the ImQuest BioSciences business unit and the status of the post-merger stock conversion process.

Anika Therapeutics, Inc., a global joint preservation company focused on early intervention orthopedics, will debut their full joint preservation and restoration product portfolio at the 2021 American Academy of Orthopedic Surgeons Annual Meeting in San Diego, California September 1-3.

NuProbe Global, a global molecular diagnostics company based in Shanghai, China and Houston, Texas, and Bionano Genomics, based in San Diego, California, have entered into a procurement and collaboration agreement.

SCIEX, a global leader in life science analytical technologies and Danaher operating company, presents the latest capillary electrophoresis solution, the BioPhase 8800 system.

ValnevaSE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate in 1-on-1 meetings with institutional investors at the Goldman Sachs Eleventh Annual Biotech Symposium on September 7, 2021.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual H.C. Wainwright 23rd Annual Global Investment Conference.

Cytokinetics, Incorporated announced that on August 31, 2021 it granted stock options to purchase an aggregate of 113,600 shares of common stock to 10 new employees, whose employment commenced in August 2021, as a material inducement to their employment.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced its decision to discontinue development of ABI-H2158 (2158) following the observation of elevated ALT levels consistent with drug-induced hepatotoxicity in an ongoing Phase 2 trial.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted nine newly-hired employees options to purchase an aggregate of 89,000 shares of Akebia’s common stock on August 31, 2021, as inducements material to each such employee’s entering into employment with Akebia.